HBL serves as a precedent in biotech financing, allowing public investment in a holding entity that includes companies based on intellectual property generated by Hadassah University Hospital. The company is held by public investors, Hadasit, and Consensus Business Group. HBL provides investment exposure to a cluster of six biotech companies, all based on inventions developed and owned by Hadassah University Hospital. As a technology transfer company, Hadasit aims to commercialize the intellectual property and R&D capabilities generated by Hadassah. Hadasit Bio-Holdings supports its portfolio companies in advancing towards Phase II clinical trials, providing assistance in pre-clinical trials, manufacturing, regulatory, and business development tasks.